Advanced searches left 3/3

Migraine - DOAJ

Summarized by Plex Scholar
Last Updated: 22 June 2022

* If you want to update the article please login/register

fMRI Findings in Cortical Brain Networks Interactions in Migraine Following Repetitive Transcranial Magnetic Stimulation

Based on results from functional MRI. Materials and MethodsThis study, a total of 19 patients with episodic migraine without aura underwent a 5-day course of rTMS of the frontotemporo-parietal junction bilaterally, with a 96 percent response in 900 pulses. Results. Network changes in functional connectivity in the brain's neural networks during and after therapy were found through independent component analysis.

Source link: https://doi.org/10.3389/fneur.2022.915346


Results of treating Patients with Chronic Migraine with OnabotulinumtoxinA alone Versus Its Combination with Other Prophylactic Drugs

This study was conducted from November 2019 to January 2021 and was conducted in conjunction with other oral prophylactics. Methods and Objectives: The aim of the study was to determine the safety of onabotulinumtoxinA injection at Almoosa Specialized Hospital in Saudi Arabia's continuous migraine clinic. Onabotulinum toxin injection is highly effective in treating patients with chronic daily migraine, reducing the number and severity of migraine attacks per month, as well as improving migraine quality in migraine patients.

Source link: https://doi.org/10.21608/ijma.2022.116352.1430


The Characteristics of White Matter Hyperintensities in Patients With Migraine

BackgroundThe presence of white matter hyperintensities in migraine is well documented, but the location of WMH in migraine patients is insufficiently investigated. paraphrasedoutput:MethodsIn total, 263 patients with migraine were enrolled in the American Registry for Migraine Research, a semiquantitative scale for categorizing WMH in periventricular, lobar, basal ganglia, and infratentorial areas, with a modified version of the Scheltens visual rating scale for determining WMH in periventricular, lobar, basal ganglia, and infratentorial regions in this study. According to results, 95 patients had no WMHs on axial T2 and FLAIR imaging, and 168 patients had WMHs, according to the scale's criteria. Describing the characteristics of WMH in migraine patients and comparing them to WMHs attributable to other etiologies may be useful in creating classificationifiers that can distinguish between migraine-specific WMH and other causes of WMH.

Source link: https://doi.org/10.3389/fpain.2022.852916


CGRP and PACAP-38 play an important role in diagnosing pediatric migraine

We prospectively investigated CGRP and PACAP-38 plasma levels in children with migraine during ictal and interictal years, comparing the findings between migraine patients with aura and without aura, and those with aura. P CGRP > PACAP-38 results: m crate-38 and CGRP levels in migraine patients during the ictal and interictal periods were higher than those in controls P CAP-38 and CGRP-38. Conclusions Our research showed that pediatric migraine sufferers had almost identical rises in both CGRP and PACAP scores, indicating that CGRP and PACAP-38 may collaborate to play a key role in pediatric migraine. Higher CGRP levels were found in the ictal phase than in the interictal phase and with higher aura groups than without the aura group, indicating that CGRP may play a role in pain and aura development.

Source link: https://doi.org/10.1186/s10194-022-01435-7


Galcanezumab effect on “whole pain burden” and multidimensional outcomes in migraine patients with previous unsuccessful treatments: a real-world experience

Galcanezumab has been shown to be safe and effective in migraine prevention in clinical trials. Abstract of the study Gallcanezumab has been tested extensively. However, real-life results are still lacking and ignore the effect of galcanezumab on those key migraine causes that are directly contributing to migraine symptoms. Herein we detail the clinical experience from an Italian real-world setting using galcanezumab in patients with migraine from previous unsuccessful preventive treatments. Methods Forty-three patients with migraine and the inability of at least three migraine preventive medication classes were included in monthly galcanezumab 120 mg s. c. at the first administration and after 3 and 6 months, patients underwent extensive interviews to determine disease-specific characteristics. Moreover, an increase in headache pain frequency and duration, as well as in scores assessing migraine-related disability and impact, depressive and anxious symptoms, and pain catastrophizing were all observed.

Source link: https://doi.org/10.1186/s10194-022-01436-6


Real-world experience of erenumab in patients with chronic or episodic migraine in the UAE

In real-world settings in patients with migraine in the United Arab Emirates, we investigated the usage patterns and effectiveness of erenumab in real-world settings in patients with migraine. In real-world settings in the UAE, the primary aim was to identify usage patterns of erenumab in patients with chronic migraine or episodic migraine. Similar decreases in MHD and MSMD as well as clinical benefit in CM or EM were seen with erenumab monotherapy or erenumab add-on therapy, with or without dose escalation, as well as treatment nau00efve or u22651 previous preventive treatment failures, with further clinical value in the erenumab add-on therapy and dose increase to 140 mg subgroups. Patients prescribed erenumab in the UAE were observed clinically significant reductions in MHD and MSMD at all time points, according to the author's real-world report.

Source link: https://doi.org/10.1186/s12883-022-02710-5


OnabotulinumtoxinA in chronic migraine: is the response dose dependent?

The aim of the current research was to investigate the safety of various doses of the onabotulinumtoxinA therapy in patients with persistent migraines. Methods This is a retrospective paired comparison study of patients with chronic migraine who were given at least three rounds of 150 units of onabotulinumtoxinA and at least three rounds of 200 units of onabotulinumtoxinA. After an increase in the onabotulinumtoxinA dose, respectively, the headache days and severe headache days decreased from 13. 77 and 5. 88 u00b1 6. 83 to 11. 01 - 0508 b1 4. 0 days to 11. 02 u00b1 4. 89 days. The 200 units were more effective than the 150 units of the onabotulinumtoxinA treatment; the headache location and the duration of the onabotulinumtoxinA 150 units were unrelated; patients continued to receive the higher dose of onabotulinumtoxinA; and persistent as patients continued to receive the higher dose of onabotulinumtoxinA. Conclusion We discovered that an increase in the onabotulinumtoxinA causes less headache and more headache days.

Source link: https://doi.org/10.1186/s12883-022-02742-x


Single midline incision approach for decompression of greater, lesser and third occipital nerves in migraine surgery

Abstract Background The common treatment for occipital migraine surgery in the posterior neck involved three separate surgical incisions to decompress the greater occipital nerves, less occipital nerves, and third occipital nerves. All six occipital nerves were decompressed by one, vertical midline incision technique. The GON and TON were discovered at 3. 5 and 6. 2 cm, respectively, inferior to a line bisecting the external auditory canal and 1. 5 cm lateral to the midline, respectively, with the midline incision. The LON was identified as 6-cm inferior and 6. 5-cm medial to a line bisecting the EAC in the plane just above the deep cervical fascia's investing layer until the sternocleidomastoid's posterior border was encountered. Conclusions An easy midline incision strategy enables the successful identification and decompression of all six occipital nerves in migraine surgery.

Source link: https://doi.org/10.1186/s12893-022-01675-z


Relating the cortical visual contrast gain response to spectroscopy-measured excitatory and inhibitory metabolites in people who experience migraine.

Objectives This research was done to see if the physical response to flickering checkerboard patterns measured using electroencephalography could be related to excitatory or inhibitory metabolite levels measured using ultra-high magnetic resonance spectroscopy. Background Electrophysiological research has revealed altered visual amplitudes and contrast gain responses to high contrast flickering patterns in migraine sufferers. Methods MRS-measured metabolite levels were determined from the occipital cortex of 18 participants with migraine and 18 non-headache controls, according to MRS-measured metabolite tests. Response functions were collected on separate days from a group of ten people with migraine and 12 non-headache controls on separate days. Conclusions Neither at the time of the checkerboard timepoint showed a significant difference in GABA and glutamate levels. Conclusions Our results show that the mechanisms that prompted contrast-flickering stimulus aversion are not reflected by gross changes in metabolic activity in the primary visual cortex, according to the authors.

Source link: https://doi.org/10.1371/journal.pone.0266130


Migraine in the workplace

People with migraine, work efficiency, and interpersonal relationships at work all have a major effect on people with migraine. People with migraines want to work, so they do their best to function despite the numerous migraine-related and related symptoms. People are less than half effective during a migraine attack due to the pain, migraines, attack unpredictability, migraine comorbidities, under-diagnosis, and stigma. Fortunately, there are ways to assist people with migraines in the workplace and raise their productivity, including workplace migraine education, workplace migraine education, and compensation policies, migraine-friendly workplace environments, migraine treatment optimization, and advocacy.

Source link: https://doi.org/10.1016/j.ensci.2022.100408

* Please keep in mind that all text is summarized by machine, we do not bear any responsibility, and you should always check original source before taking any actions

* Please keep in mind that all text is summarized by machine, we do not bear any responsibility, and you should always check original source before taking any actions